keyword
MENU ▼
Read by QxMD icon Read
search

Parkinson's and PET scan

keyword
https://www.readbyqxmd.com/read/29075830/presynaptic-dopamine-depletion-determines-the-timing-of-levodopa-induced-dyskinesia-onset-in-parkinson-s-disease
#1
Han Soo Yoo, Seok Jong Chung, Su Jin Chung, Hyojeong Moon, Jung Su Oh, Jae Seung Kim, Jin Yong Hong, Byoung Seok Ye, Young Ho Sohn, Phil Hyu Lee
PURPOSE: Reduced presynaptic dopaminergic activity plays an important role in the development of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD). In this study, we investigated whether dopaminergic function in the nigrostriatal system is associated with the timing of LID onset. METHODS: From among 412 drug-naive PD patients who underwent a dopamine transporter (DAT) PET scan during their baseline evaluation, we enrolled 65 patients who developed LID during a follow-up period of >2 years...
October 26, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29064601/differential-involvement-of-nigral-subregions-in-idiopathic-parkinson-s-disease
#2
Young Hee Sung, Jongho Lee, Yoonho Nam, Hyeong-Geol Shin, Young Noh, Dong Hoon Shin, Eung Yeop Kim
In this study, the prevalence of abnormality in putative nigrosome 1 and nigrosome 4 (N1 and N4, respectively) was investigated in early versus late-stage idiopathic Parkinson's disease (IPD) patients. A total of 128 IPD patients (early stage[n = 89]; late stage[n = 39]) and 15 healthy subjects were scanned for high-resolution (0.5 × 0.5 × 1.0 mm(3) ) multiecho gradient-recalled echo MRI and dopamine transporter PET imaging. The MRI data were processed for susceptibility map-weighted imaging (SMWI) to improve a contrast-to-noise ratio, and the images were resliced at 0...
October 24, 2017: Human Brain Mapping
https://www.readbyqxmd.com/read/29047416/lessons-learned-about-f-18-av-1451-off-target-binding-from-an-autopsy-confirmed-parkinson-s-case
#3
Marta Marquié, Eline E Verwer, Avery C Meltzer, Sally Ji Who Kim, Cinthya Agüero, Jose Gonzalez, Sara J Makaretz, Michael Siao Tick Chong, Prianca Ramanan, Ana C Amaral, Marc D Normandin, Charles R Vanderburg, Stephen N Gomperts, Keith A Johnson, Matthew P Frosch, Teresa Gómez-Isla
[F-18]-AV-1451 is a novel positron emission tomography (PET) tracer with high affinity to neurofibrillary tau pathology in Alzheimer's disease (AD). PET studies have shown increased tracer retention in patients clinically diagnosed with dementia of AD type and mild cognitive impairment in regions that are known to contain tau lesions. In vivo uptake has also consistently been observed in midbrain, basal ganglia and choroid plexus in elderly individuals regardless of their clinical diagnosis, including clinically normal whose brains are not expected to harbor tau pathology in those areas...
October 19, 2017: Acta Neuropathologica Communications
https://www.readbyqxmd.com/read/29046477/increased-putamen-hypercapnic-vasoreactivity-in-levodopa-induced-dyskinesia
#4
Vincent A Jourdain, Katharina A Schindlbeck, Chris C Tang, Martin Niethammer, Yoon Young Choi, Daniel Markowitz, Amir Nazem, Dominic Nardi, Nicholas Carras, Andrew Feigin, Yilong Ma, Shichun Peng, Vijay Dhawan, David Eidelberg
In a rodent model of Parkinson's disease (PD), levodopa-induced involuntary movements have been linked to striatal angiogenesis - a process that is difficult to document in living human subjects. Angiogenesis can be accompanied by localized increases in cerebral blood flow (CBF) responses to hypercapnia. We therefore explored the possibility that, in the absence of levodopa, local hypercapnic CBF responses are abnormally increased in PD patients with levodopa-induced dyskinesias (LID) but not in their nondyskinetic (NLID) counterparts...
October 19, 2017: JCI Insight
https://www.readbyqxmd.com/read/28918694/brain-metabolic-correlates-of-fatigue-in-parkinson-s-disease-a-pet-study
#5
Li Zhang, Tiannv Li, Yongsheng Yuan, Qing Tong, Siming Jiang, Min Wang, Jianwei Wang, Jian Ding, Qinrong Xu, Kezhong Zhang
The neural bases of fatigue in Parkinson's disease (PD) remain uncertain. We aimed to assess the brain metabolic correlates of fatigue in patients with PD. Twenty-seven PD patients without clinically relevant depression (17-item Hamilton Depression Rating Scale [HAMD] score ≥ 14), apathy (Apathy Scale [AS] score ≥ 14) and excessive daytime somnolence (Epworth Sleepiness Scale [ESS] score ≥ 10) were evaluated with Fatigue Severity Scale (FSS). Each patient had an F-18 fluorodeoxyglucose PET (FDG-PET) scan...
September 18, 2017: International Journal of Neuroscience
https://www.readbyqxmd.com/read/28895043/effects-of-long-term-caffeine-consumption-on-the-adenosine-a1-receptor-in-the-rat-brain-an-in-vivo-pet-study-with-18-f-cpfpx
#6
Danje Nabbi-Schroeter, David Elmenhorst, Angela Oskamp, Stefanie Laskowski, Andreas Bauer, Tina Kroll
PURPOSE: Caffeine, a nonselective antagonist of adenosine receptors, is the most popular psychostimulant worldwide. Recently, a protective role of moderate chronic caffeine consumption against neurodegenerative diseases such as Alzheimer's and Parkinson's disease has been discussed. Thus, aim of the present study was an in vivo investigation of effects of long-term caffeine consumption on the adenosine A1 receptor (A1AR) in the rat brain. PROCEDURES: Sixteen adult, male rats underwent five positron emission tomography (PET) scans with the highly selective A1AR radioligand [(18)F]CPFPX in order to determine A1AR availability...
September 11, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28884232/-18-f-av-1451-binding-to-neuromelanin-in-the-substantia-nigra-in-pd-and-psp
#7
Sarah Coakeley, Sang Soo Cho, Yuko Koshimori, Pablo Rusjan, Christine Ghadery, Jinhee Kim, Anthony E Lang, Sylvain Houle, Antonio P Strafella
This study investigated binding of [(18)F]AV-1451 to neuromelanin in the substantia nigra of patients with Parkinson's disease (PD) and progressive supranuclear palsy (PSP). [(18)F]AV-1451 is a positron emission tomography radiotracer designed to bind pathological tau. A post-mortem study using [(18)F]AV-1451 discovered off-target binding properties to neuromelanin in the substantia nigra. A subsequent clinical study reported a 30% decrease in [(18)F]AV-1451 binding in the midbrain of PD patients. A total of 12 patients and 10 healthy age-matched controls were recruited...
September 7, 2017: Brain Structure & Function
https://www.readbyqxmd.com/read/28879087/chronic-exposure-to-dopamine-agonists-affects-the-integrity-of-striatal-d2-receptors-in-parkinson-s-patients
#8
Marios Politis, Heather Wilson, Kit Wu, David J Brooks, Paola Piccini
We aimed to investigate the integrity and clinical relevance of striatal dopamine receptor type-2 (D2R) availability in Parkinson's disease (PD) patients. We studied 68 PD patients, spanning from early to advanced disease stages, and 12 healthy controls. All participants received one [(11)C]raclopride PET scan in an OFF medication condition for quantification of striatal D2R availability in vivo. Parametric images of [(11)C]raclopride non-displaceable binding potential were generated from the dynamic [(11)C]raclopride scans using implementation of the simplified reference tissue model with cerebellum as the reference tissue...
2017: NeuroImage: Clinical
https://www.readbyqxmd.com/read/28734065/fdg-pet-dopamine-transporter-spect-and-olfaction-combining-biomarkers-in-rem-sleep-behavior-disorder
#9
Sanne K Meles, David Vadasz, Remco J Renken, Elisabeth Sittig-Wiegand, Geert Mayer, Candan Depboylu, Kathrin Reetz, Sebastiaan Overeem, Angelique Pijpers, Fransje E Reesink, Teus van Laar, Lisette Heinen, Laura K Teune, Helmut Höffken, Marcus Luster, Karl Kesper, Sofie M Adriaanse, Jan Booij, Klaus L Leenders, Wolfgang H Oertel
BACKGROUND: Idiopathic REM sleep behavior disorder is a prodromal stage of Parkinson's disease and dementia with Lewy bodies. Hyposmia, reduced dopamine transporter binding, and expression of the brain metabolic PD-related pattern were each associated with increased risk of conversion to PD. The objective of this study was to study the relationship between the PD-related pattern, dopamine transporter binding, and olfaction in idiopathic REM sleep behavior disorder. METHODS: In this cross-sectional study, 21 idiopathic REM sleep behavior disorder subjects underwent (18) F-fluorodeoxyglucose PET, dopamine transporter imaging, and olfactory testing...
October 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28694016/-18-f-fdopa-positron-emission-tomography-in-manganese-exposed-workers
#10
Susan R Criswell, Susan Searles Nielsen, Mark Warden, Joel S Perlmutter, Stephen M Moerlein, Hubert P Flores, John Huang, Lianne Sheppard, Noah Seixas, Harvey Checkoway, Brad A Racette
Occupational manganese (Mn) exposure is associated with the development of parkinsonism; however, the mechanism of neurotoxicity is unknown. Brain positron emission tomography (PET) imaging provides a non-invasive method of assessing dopamineric neuronal function. 6-[(18)F]fluoro-L-DOPA (FDOPA) PET reflects in-vivo nigrostriatal function, but results in Mn exposure are conflicting. The objective of this study was to investigate the association between Mn exposure secondary to occupational welding, FDOPA striatal uptake, and clinical parkinsonism as measured by Unified Parkinson Disease Rating Scale motor subscore 3 (UPDRS3) scores...
July 8, 2017: Neurotoxicology
https://www.readbyqxmd.com/read/28579485/cerebral-metabolic-change-in-parkinson-s-disease-patients-with-anxiety-a-fdg-pet-study
#11
Xixi Wang, Jiejin Zhang, Yongsheng Yuan, Tiannv Li, Li Zhang, Jian Ding, Siming Jiang, Junyi Li, Lin Zhu, Kezhong Zhang
OBJECT: To detect the cerebral metabolic bases of Parkinson's disease (PD) patients with anxiety. METHODS: Totally 28 idiopathic PD patients without depression (17-item Hamilton Depression Rating Scale, HAMD score <14) were enrolled in our study. All subjects were classified into PD with anxiety (PD-A) (n=13) and PD without anxiety (PD-NA) (n=15) by cutoff score of 11 according to Hamilton Anxiety Rating Scale (HAMA). Besides, age- and gender- matched healthy controls (HCs) (n=15) were selected...
July 13, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28568506/pbb3-imaging-in-parkinsonian-disorders-evidence-for-binding-to-tau-and-other-proteins
#12
Alexandra Perez-Soriano, Julieta E Arena, Katie Dinelle, Qing Miao, Jessamyn McKenzie, Nicole Neilson, Andreas Puschmann, Paul Schaffer, Hitoshi Shinotoh, Jenna Smith-Forrester, Elham Shahinfard, Nasim Vafai, Daryl Wile, Zbigniew Wszolek, Makoto Higuchi, Vesna Sossi, A Jon Stoessl
BACKGROUND AND OBJECTIVES: To study selective regional binding for tau pathology in vivo, using PET with [(11) C]PBB3 in PSP patients, and other conditions not typically associated with tauopathy. METHODS: Dynamic PET scans were obtained for 70 minutes after the bolus injection of [(11) C]PBB3 in 5 PSP subjects, 1 subject with DCTN1 mutation and PSP phenotype, 3 asymptomatic SNCA duplication carriers, 1 MSA subject, and 6 healthy controls of similar age. Tissue reference Logan analysis was applied to each region of interest using a cerebellar white matter reference region...
July 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28542444/regional-brain-amyloid-%C3%AE-accumulation-associates-with-domain-specific-cognitive-performance-in-parkinson-disease-without-dementia
#13
Rizwan S Akhtar, Sharon X Xie, Yin J Chen, Jacqueline Rick, Rachel G Gross, Ilya M Nasrallah, Vivianna M Van Deerlin, John Q Trojanowski, Alice S Chen-Plotkin, Howard I Hurtig, Andrew D Siderowf, Jacob G Dubroff, Daniel Weintraub
Parkinson disease patients develop clinically significant cognitive impairment at variable times over their disease course, which is often preceded by milder deficits in memory, visuo-spatial, and executive domains. The significance of amyloid-β accumulation to these problems is unclear. We hypothesized that amyloid-β PET imaging by 18F-florbetapir, a radiotracer that detects fibrillar amyloid-β plaque deposits, would identify subjects with global cognitive impairment or poor performance in individual cognitive domains in non-demented Parkinson disease patients...
2017: PloS One
https://www.readbyqxmd.com/read/28490469/management-impact-of-imaging-brain-vesicular-monoamine-transporter-type-2-vmat2-in-clinically-uncertain-parkinsonian-syndrome-cups-with-18-f-av133-and-pet
#14
Paschal Kevin Alexander, Yennie Lie, Gareth Jones, Chomalaven Sivaratnam, Svetlana Bozinovski, Rachel S Mulligan, Kenneth Young, Victor Luis Villemagne, Christopher C Rowe
Objectives: Idiopathic Parkinson's disease (iPD) is a common neurodegenerative disorder where misdiagnosis occurs in up to 30% of patients after initial assessment and in 10-15% even after long-term follow-up. Vesicular monoamine transporter type II (VMAT2) imaging with Positron Emission Tomography (PET) allows assessment of the integrity of the presynaptic dopaminergic pathway. We investigated the management impact of VMAT2 imaging in patients with Clinically Uncertain Parkinsonian Syndromes (CUPS). Methods: Forty-seven patients with CUPS (56...
May 10, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28451991/-18-f-fp-dtbz-pet-study-in-a-lactacystin-treated-rat-model-of-parkinson-disease
#15
Chi-Chang Weng, Siao-Lan Huang, Zi-An Chen, Kun-Ju Lin, Ing-Tsung Hsiao, Tzu-Chen Yen, Mei-Ping Kung, Shiaw-Pyng Wey, Ching-Han Hsu
OBJECTIVE: Lactacystin has been used to establish rodent models of Parkinson disease (PD), with cerebral α-synuclein inclusions. This study evaluated the uptake of [(18)F]9-fluoropropyl-(+)-dihydrotetrabenazine ([(18)F]FP-(+)-DTBZ), a vesicular monoamine transporter type 2 (VMAT2)-targeting radiotracer, through positron emission tomography (PET) in lactacystin-treated rat brains. METHODS: Adult male Sprague-Dawley rats were randomly treated with a single intracranial dose of lactacystin (2 or 5 μg) or saline (served as the sham control) into the left medial forebrain bundle...
August 2017: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/28440890/fluorescence-and-autoradiographic-evaluation-of-tau-pet-ligand-pbb3-to-%C3%AE-synuclein-pathology
#16
Shunsuke Koga, Maiko Ono, Naruhiko Sahara, Makoto Higuchi, Dennis W Dickson
BACKGROUND: The tau PET ligand 2-((1E,3E)-4-(6-([(11) C]methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol ([(11) C]PBB3) binds to a wide range of tau pathology; however, binding property of PBB3 to non-tau inclusions remains unknown. To clarify whether [(11) C]PBB3 binds to α-synuclein pathology, reactivity of PBB3 was assessed by in vitro fluorescence and autoradiographic labeling of brain sections from α-synucleinopathies patients. METHOD: Of 10 pure Lewy body disease and 120 multiple system atrophy (MSA) cases in the Mayo Clinic brain bank, we selected 3 Lewy body disease and 4 MSA cases with a range of α-synuclein severity based on the quantitative analysis of α-synuclein burden...
June 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28407307/adenosine-a1-receptors-measured-with-11-c-mpdx-pet-in-early-parkinson-s-disease
#17
Masahiro Mishina, Kenji Ishii, Yuichi Kimura, Masahiko Suzuki, Shin Kitamura, Kenji Ishibashi, Muneyuki Sakata, Keiichi Oda, Shiro Kobayashi, Kazumi Kimura, Kiichi Ishiwata
Adenosine A1 receptors (A1 Rs) interact negatively with dopamine D1 receptors (D1 Rs) in neurons of the basal ganglia's direct pathway, while adenosine A2A receptors (A2A Rs) negatively interact with dopamine D2 receptors (D2 Rs) in indirect-pathway neurons. The aim of this study was to investigate the cerebral density of A1 Rs in Parkinson's disease (PD) in its early stages, using PET scans with the radioligand 8-dicyclopropylmethyl-1-(11) C-methyl-3-propylxanthine ((11) C-MPDX). We studied 10 drug-naïve patients with early PD...
August 2017: Synapse
https://www.readbyqxmd.com/read/28386687/abnormal-metabolic-brain-network-associated-with-parkinson-s-disease-replication-on-a-new-european-sample
#18
Petra Tomše, Luka Jensterle, Marko Grmek, Katja Zaletel, Zvezdan Pirtošek, Vijay Dhawan, Shichun Peng, David Eidelberg, Yilong Ma, Maja Trošt
PURPOSE: The purpose of this study was to identify the specific metabolic brain pattern characteristic for Parkinson's disease (PD): Parkinson's disease-related pattern (PDRP), using network analysis of [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) brain images in a cohort of Slovenian PD patients. METHODS: Twenty PD patients (age 70.1 ± 7.8 years, Movement Disorder Society Unified Parkinson's Disease Motor Rating Scale (MDS-UPDRS-III) 38.3 ± 12...
May 2017: Neuroradiology
https://www.readbyqxmd.com/read/28378615/the-utility-of-fdg-pet-in-the-differential-diagnosis-of-parkinsonism
#19
Leposava Brajkovic, Vladimir Kostic, Dragana Sobic-Saranovic, Elka Stefanova, Milica Jecmenica-Lukic, Ana Jesic, Milica Stojiljkovic, Strahinja Odalovic, Francesca Gallivanone, Isabella Castiglioni, Branislava Radovic, Goran Trajkovic, Vera Artiko
INTRODUCTION: Differential diagnosis of parkinsonian disorders can be difficult on clinical grounds, especially in the early stage. Recent advancements in 18-F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging reveals different patterns of regional glucose metabolism in idiopathic Parkinson's disease (IPD) and atypical parkinsonian syndromes, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), which may help differentiating between these conditions...
April 5, 2017: Neurological Research
https://www.readbyqxmd.com/read/28336296/serotonin-and-dopamine-transporter-pet-changes-in-the-premotor-phase-of-lrrk2-parkinsonism-cross-sectional-studies
#20
Daryl J Wile, Pankaj A Agarwal, Michael Schulzer, Edwin Mak, Katherine Dinelle, Elham Shahinfard, Nasim Vafai, Kazuko Hasegawa, Jing Zhang, Jessamyn McKenzie, Nicole Neilson, Audrey Strongosky, Ryan J Uitti, Mark Guttman, Cyrus P Zabetian, Yu-Shin Ding, Mike Adam, Jan Aasly, Zbigniew K Wszolek, Matthew Farrer, Vesna Sossi, A Jon Stoessl
BACKGROUND: People with Parkinson's disease can show premotor neurochemical changes in the dopaminergic and non-dopaminergic systems. Using PET, we assessed whether dopaminergic and serotonin transporter changes are similar in LRRK2 mutation carriers with Parkinson's disease and individuals with sporadic Parkinson's disease, and whether LRRK2 mutation carriers without motor symptoms show PET changes. METHODS: We did two cross-sectional PET studies at the Pacific Parkinson's Research Centre in Vancouver, BC, Canada...
May 2017: Lancet Neurology
keyword
keyword
60911
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"